NO2399993T3 - - Google Patents

Info

Publication number
NO2399993T3
NO2399993T3 NO10743584A NO10743584A NO2399993T3 NO 2399993 T3 NO2399993 T3 NO 2399993T3 NO 10743584 A NO10743584 A NO 10743584A NO 10743584 A NO10743584 A NO 10743584A NO 2399993 T3 NO2399993 T3 NO 2399993T3
Authority
NO
Norway
Application number
NO10743584A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2399993T3 publication Critical patent/NO2399993T3/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO10743584A 2009-02-20 2010-02-19 NO2399993T3 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009037750 2009-02-20
PCT/JP2010/001100 WO2010095455A1 (ja) 2009-02-20 2010-02-19 低免疫原性ストレプトアビジンおよびその利用

Publications (1)

Publication Number Publication Date
NO2399993T3 true NO2399993T3 (ja) 2018-02-17

Family

ID=42633742

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10743584A NO2399993T3 (ja) 2009-02-20 2010-02-19

Country Status (7)

Country Link
US (1) US8546537B2 (ja)
EP (1) EP2399993B1 (ja)
JP (1) JP5472754B2 (ja)
CN (1) CN102325884B (ja)
CA (1) CA2753048C (ja)
NO (1) NO2399993T3 (ja)
WO (1) WO2010095455A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6475630B2 (ja) * 2012-11-16 2019-02-27 イーベーアー ゲーエムベーハー ストレプトアビジン突然変異タンパク質およびそれらを使用する方法
JP6178586B2 (ja) 2013-02-20 2017-08-09 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
JP6096371B2 (ja) * 2014-02-18 2017-03-15 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
EP3353290A1 (en) * 2015-09-23 2018-08-01 European Molecular Biology Laboratory Protease-resistant streptavidin
CN109983024A (zh) 2016-11-25 2019-07-05 赛威德医疗公司 清除剂
JPWO2019230905A1 (ja) 2018-05-30 2021-06-24 国立大学法人 東京大学 ハロゲン化したビオチン改変二量体およびその利用
CN115605487A (zh) 2020-04-14 2023-01-13 国立大学法人东京大学（Jp） 生物素变体二聚体及其用途
IL302470A (en) 2020-10-30 2023-06-01 Tod SPEER Oligonucleotide-based treatments and their uses
WO2023008515A1 (ja) 2021-07-29 2023-02-02 国立大学法人 東京大学 抗原結合分子とストレプトアビジン変異体との融合タンパク質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
DE69331319T2 (de) 1992-06-09 2002-08-08 Neorx Corp Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
NZ336766A (en) * 1997-02-10 2000-08-25 United Kingdom Government Transgenic potatoes having reduced levels of alpha glucan l- or h- type tuber phosphorylase activity with reduced cold-sweetening
AU5597500A (en) * 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7148051B2 (en) * 2004-08-16 2006-12-12 E. I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤

Also Published As

Publication number Publication date
JP5472754B2 (ja) 2014-04-16
CN102325884A (zh) 2012-01-18
US8546537B2 (en) 2013-10-01
CN102325884B (zh) 2013-11-20
US20120039879A1 (en) 2012-02-16
WO2010095455A1 (ja) 2010-08-26
CA2753048C (en) 2015-11-03
EP2399993B1 (en) 2017-09-20
EP2399993A9 (en) 2012-07-18
CA2753048A1 (en) 2010-08-26
EP2399993A4 (en) 2013-07-03
JPWO2010095455A1 (ja) 2012-08-23
EP2399993A1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
BR112012012396A2 (ja)
BR112012008267A2 (ja)
BR112012003062A2 (ja)
BR112012008195A2 (ja)
BR112012000607A2 (ja)
BRPI0925311A2 (ja)
BRPI0924307A2 (ja)
BR112012003080A2 (ja)
BR122021004633A2 (ja)
BR122017024704A2 (ja)
BR112012000665A2 (ja)
BR112012003853A2 (ja)
BR112012012080A2 (ja)
BR112012009797A2 (ja)
BR112012009446A2 (ja)
BR112012009703A2 (ja)
BR112012010357A2 (ja)
BR112012007656A2 (ja)
BR112012002627A2 (ja)
BR112012000159A2 (ja)
BR112012014856A2 (ja)
BRPI0924534A2 (ja)
BR112012007672A2 (ja)
BR112012007654A2 (ja)
BR112012005951A2 (ja)